The impact of HER2 overexpression on the miRNA and circRNA transcriptomes in two breast cell lines and their vesicles.


Journal

Pharmacogenomics
ISSN: 1744-8042
Titre abrégé: Pharmacogenomics
Pays: England
ID NLM: 100897350

Informations de publication

Date de publication:
05 2019
Historique:
entrez: 25 5 2019
pubmed: 28 5 2019
medline: 14 4 2020
Statut: ppublish

Résumé

HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and circRNAs in the cell-lines HB4a and C5.2, where the latter is a HER2-overexpressing clone of the former, and also from two different populations of their secreted extracellular vesicles. Whereas circRNA-levels were stable, we found at least 16 miRNAs apparently modulated by HER2-expression. The miR223-3p, miR-421 and miR-21-5p were validated in an independent cohort of 431 breast cancer patients from The Cancer Genome Atlas (TCGA). The consistent modulation of these molecules and their possible involvement in the HER2-axis makes them promising new targets to overcome HER2-activation.

Identifiants

pubmed: 31124410
doi: 10.2217/pgs-2018-0182
doi:

Substances chimiques

MIRN21 microRNA, human 0
MIRN421 microRNA, human 0
MicroRNAs 0
RNA, Circular 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

493-502

Auteurs

Maria Galli de Amorim (M)

Laboratory of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Curso de Pós-graduação em Oncologia, Fundação Antônio Prudente, São Paulo, SP, Brazil.

Gabriela Branco (G)

Laboratory of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Curso de Pós-graduação em Oncologia, Fundação Antônio Prudente, São Paulo, SP, Brazil.

Renan Valieris (R)

Laboratory of Computational Biology, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Emilio Tarcitano (E)

Laboratory of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Curso de Pós-graduação em Oncologia, Fundação Antônio Prudente, São Paulo, SP, Brazil.

Israel Tojal da Silva (I)

Laboratory of Computational Biology, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Luiza Ferreira de Araújo (L)

Laboratory of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Diana Noronha Nunes (D)

Laboratory of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.

Emmanuel Dias-Neto (E)

Laboratory of Medical Genomics, AC Camargo Cancer Center, São Paulo, SP, Brazil.
Laboratório de Neurociências Alzira Denise Hertzog Silva (LIM27), Instituto de Psiquiatria, Faculdade de Medicina da Universidade de São Paulo (USP), São Paulo, SP, Brazil.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH